Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06477185Phase 2Recruiting

Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline

Role: collaborator

NCT05909358Phase 1Not Yet Recruiting

Solidarity/Tokomeza Ebola Trial

Role: collaborator

NCT05897203Phase 2Unknown

Clinical Trial of Natural Therapeutics for COVID-19 and Other Acute Respiratory Viral Infections

Role: collaborator

All 3 trials loaded